Phase II data for Blautix® showing clinical activity in irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D).Commencement and expansion of Part B of Phase I/II clinical trial of MRx0518 in combination with Keytruda®, with inclusion of additional tumor type cohorts and additional US sites added.Launched a third clinical trial of MRx0518, in pancreatic cancer in combination with stereotactic radiotherapy.Presented the first clinical monotherapy data for a Live Biotherapeutic in oncology with data from Part A of our clinical trial of MRx0518 in the neoadjuvant setting.Announced safety and proof-of-concept clinical efficacy data for lead Live Biotherapeutic MRx0518 in combination with checkpoint inhibitor (ICI) Keytruda® in heavily pre-treated patients with non-small cell lung cancer and renal cell carcinoma refractory to prior ICIs.Basic and diluted loss per share of 22.80 pence (2019: 36.75 pence).Adjusted loss per share of 22.80 pence (2019: 40.81pence).Loss for the year and total comprehensive income for the year of £25.9 million (2019: £23.7 million).Cash and cash equivalents (including cash on deposit) of £8.8 million (2019: £3.8 million). ![]() ![]() 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2020.Īll details stated hereafter relate to the UK IFRS accounts the Group also produces US GAAP accounts, the details of which are included in the Form 20-F to be filed with the U.S.
0 Comments
Leave a Reply. |